Robert A Stewart
CIK 1476493 · President and CEO · last filed 2026-01-27
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AMRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MORRISTOWN, NJ 07960
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRMD | Director | 66,453 | $7.94 | $527.6K | $43.7K | 6 | 2026-01-27 |
| AMRX | President and CEO | 100,277 | $21.02 | $2.11M | $202.6K | 4 | 2019-05-09 |
| Allergan plc (AGN) Delisted | Chief Operating Officer | 66,650 | — | — | $0 | 5 | 2018-01-02 |
| ACT | Chief Operating Officer | 44,225 | $48.29 | $2.14M | $0 | 2 | 2015-03-09 |
| Actavis, Inc. (WPI) Delisted | Pres-Global Operations | 77,154 | — | — | $0 | 7 | 2012-11-02 |
Recent Filings · Page 2 of 4
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-01-02 | Allergan plc (AGN) Delisted | Tax (F) | −2,149 | -$351.5K | EDGAR |
| 2017-10-30 | Allergan plc (AGN) Delisted | Exer (M) | +12,427 | $0 | EDGAR |
| 2017-04-04 | Allergan plc (AGN) Delisted | Grant (A) | +7,362 | $1.75M | EDGAR |
| 2017-03-07 | Allergan plc (AGN) Delisted | Tax (F) | −761 | -$186.9K | EDGAR |
| 2017-02-03 | Allergan plc (AGN) Delisted | Mixed | +1,571 | $360.3K | EDGAR |
| 2015-03-09 | ACT | Mixed | +3,564 | -$296.9K | EDGAR |
| 2014-07-03 | — | Grant (A) | — | $0 | |
| 2013-12-10 | — | Sell (S) | −8,000 | -$1.33M | |
| 2013-11-19 | — | Sell (S) | −10,000 | -$1.64M | |
| 2013-11-13 | — | Sell (S) | −12,000 | -$1.90M |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.